This is an open label 8-week trial of modafinil up to 400 mg daily added to a stable antipsychotic regimen to evaluate the effect modafinil on cognition, sedation, and weight in patients with chronic schizophrenia. We hypothesize that modafinil, a wake-promoting agent, will lead to improved cognition, increased wakefulness, and decreased weight in patients with schizophrenia who are on stable antipsychotic regimens
This study was withdrawn due to no source of funding to implement the study. No participants were enrolled for this study.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Modafinil up to 400 mg daily will be added to a stable antipsychotic regimen
Cognitive changes as measured by the NIH MATRICS - Consensus Cognitive Battery (MCCB)
Study withdrawn due to lack of funds.
Time frame: 8 weeks
Sedation and weight changes
Study withdrawn due to lack of funds.
Time frame: 8 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.